Twenty-three women with chronic heavy anovulatory uterine bleeding and severe iron-deficiency anemia received six months' treatment with goserelin, a gonadotropin releasing hormone agonist, administered as a monthly subcutaneous depot. After two months of treatment, all patients were amenorrheic and subsequent spotting was reported on only nine occasions. Laboratory results showed the following values: mean hemoglobin before treatment, 7.9 g/dL-13.8 g/dL at six months (+75%); mean hematocrit, 26.3%-41.6% (+58); mean serum iron, 19.8 micrograms/dL-63.3 micrograms/dL (+134%) and mean serum ferritin, 6.2 ng/mL-35.3 ng/mL (+469%). The endometrial hyperplasia observed in 11 subjects showed regression at follow-up suction biopsy. Gonadotropin releasing hormone agonists administered in a depot formulation for a few months in highly selected patients with severe anemia associated with heavy anovulatory uterine bleeding are practical, safe and effective, may avoid blood transfusions and could be used as a first line of treatment.
Gonadotropin releasing hormone agonist for chronic anovulatory uterine bleeding and severe anemia / P. Vercellini, L. Fedele, R. Maggi, N. Vendola, L. Bocciolone, A. Colombo. - In: JOURNAL OF REPRODUCTIVE MEDICINE. - ISSN 0024-7758. - 38:2(1993 Feb), pp. 127-129.
|Titolo:||Gonadotropin releasing hormone agonist for chronic anovulatory uterine bleeding and severe anemia|
|Parole Chiave:||Delayed-Action Preparations; Humans; Adult; Goserelin; Anemia, Hypochromic; Middle Aged; Menorrhagia; Anovulation; Female|
|Settore Scientifico Disciplinare:||Settore MED/40 - Ginecologia e Ostetricia|
|Data di pubblicazione:||feb-1993|
|Appare nelle tipologie:||01 - Articolo su periodico|